Linked Life Data

16151394

Source:http://linkedlifedata.com/resource/pubmed/id/16151394

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2005-9-9
pubmed:abstractText
Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1087-0156
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1073-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Monoclonal antibody successes in the clinic.
pubmed:affiliation
Tufts University Center for the Study of Drug Development (CSDD), 192 South Street, Suite 550, Boston, Massachusetts 02111, USA. janice.reichert@tufts.edu
pubmed:publicationType
Journal Article